Conférence
Notice
Langue :
Anglais
Crédits
Canal U/3S - CERIMES (Production), Canal U/3S - CERIMES (Réalisation), William T. Abraham (Intervention)
Conditions d'utilisation
Droit commun de la propriété intellectuelle
DOI : 10.60527/zwg4-g788
Citer cette ressource :
William T. Abraham. Canal-U-Médecine. (2012, 1 décembre). Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST (William T. ABRAHAM) , in CVCT 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012. [Vidéo]. Canal-U. https://doi.org/10.60527/zwg4-g788. (Consultée le 23 juillet 2025)
Logo Canal-U/Médecine
Canal-U/Médecine
S'abonner
Contacter

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST (William T. ABRAHAM)

Réalisation : 1 décembre 2012 - Mise en ligne : 25 février 2013
  • document 1 document 2 document 3
  • niveau 1 niveau 2 niveau 3
Descriptif

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012
NOVEL DIURETIC STRATEGIES IN HEART FAILURE

Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA
Webcast: Patrick ROSSIGNOL, Nancy, FRA

➢ Clinical congestion due to volume overload is the main cause of hospitalization for patients with HF and is an important therapeutic target. Failure to achieve effective and rapid correction of this condition in many patients hospitalized for HF results in prolongation of hospital stay and unfavorable after-discharge outcome.
➢ Loop diuretics, though often effective for treating congestion, have significant limitations. Discovering ways to optimize exposure to loop diuretics, achieving effective decongestion while protecting renal function, is an important goal of current clinical research in HF.
➢ Vasopressin antagonists are effective in removing large amounts of water, but not salt, in HF. The EVEREST trial in unselected acute systolic heart failure did not show benefit on CV outcomes and only a modest benefit on dyspnea. Whether vaptans in HF are still a viable option is an important question. Better targeting specific vasopressin receptors with highly selective agents, better profiling of patients more likely to benefit, combination with mineralocorticoid receptor antagonists are options that are worth exploring.
➢ Aquapharesis (Ultrafiltration: UF) has been shown to be a safe and effective therapeutic modality for correction of volume overload in hospitalized patients with HF, not responding to intravenous diuretics and vasoactive medications. Should UF replace intravenous diuretics as a first-line therapy for patients with hypervolemia admitted for HF? The validity of such a concept is being examined in the NHLBI larger CARRESS study.

Session program:
Insights from DOSE and gaps in evidence with diuretic therapy
Speaker: Alice MASCETTE, NHLBI, USA
The Vaptans story post-EVEREST.
What is next? ACTIVATE, TACTICS and BALANCE trials
Speaker: Michael FELKER, Durham, USA
Discussant: William T. ABRAHAM, Colombus, USA
Ultrafiltration for acute cardiorenal syndrome in heart failure. UNLOAD and AVOID-HF and CARRESS trial
Speaker: Gian Paolo ROSSI, Padua, ITA
Debate: New diuretic modalities: Remaining gaps in evidence or ready for clinical use?

Intervention
Thème
Disciplines :
Documentation
Le programme complet

Dans la même collection

Voir tout

Avec les mêmes intervenants et intervenantes

Sur le même thème